Literature DB >> 9852086

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.

H Pelemans1, R M Esnouf, H Jonckheere, E De Clercq, J Balzarini.   

Abstract

The highly conserved Tyr-318 is part of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-specific lipophilic pocket of human immunodeficiency virus type I reverse transcriptase (RT) and makes contact within 4 A with the NNRTIs in all reported RT/NNRTI complexes. Using site-directed mutagenesis, six mutant RTs were constructed bearing the mutations Y318H, Y318K, Y318L, Y318C, Y318W, and Y318F. We found that only the Y318W and Y318F mutant RTs retained substantial RT activity, whereas the catalytic activities of the Y318K, Y318C, Y318H, and Y318L RT mutants were less than 5% of the wild-type activity. The Y318F mutant RT retained substantial sensitivity to the majority of NNRTIs tested, whereas the Y318W mutant RT showed varying degrees of resistance to NNRTIs. Subunit-specific site-directed mutagenesis revealed that there was no difference in the catalytic activity or resistance/sensitivity spectrum toward NNRTIs regardless of whether the Tyr-318 mutation was introduced in both subunits or only in the p66 subunit of RT. Recombinant viruses harboring the Y318F or Y318W mutation in the RT showed a similar resistance/sensitivity pattern to NNRTIs as their corresponding 318 mutant recombinant RTs. Our findings stress a functional or structural role for Tyr-318 in wild-type RT and argue for the design of novel NNRTIs that interact more closely with this amino acid in the NNRTI-specific pocket of human immunodeficiency virus type I RT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852086     DOI: 10.1074/jbc.273.51.34234

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.

Authors:  Renxiang Chen; Masaru Yokoyama; Hironori Sato; Cavan Reilly; Louis M Mansky
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

2.  High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.

Authors:  Francesca Ceccherini-Silberstein; Federico Gago; Maria Santoro; Caterina Gori; Valentina Svicher; Fátima Rodríguez-Barrios; Roberta d'Arrigo; Massimo Ciccozzi; Ada Bertoli; Antonella d'Arminio Monforte; Jan Balzarini; Andrea Antinori; Carlo-Federico Perno
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

4.  Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Atsuko Hachiya; Eiichi N Kodama; Stefan G Sarafianos; Matthew M Schuckmann; Yasuko Sakagami; Masao Matsuoka; Masafumi Takiguchi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

5.  The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.

Authors:  Joeri Auwerx; Miguel Stevens; An R Van Rompay; Louise E Bird; Jingshan Ren; Erik De Clercq; Bo Oberg; David K Stammers; Anna Karlsson; Jan Balzarini
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.

Authors:  P Richard Harrigan; Mahboob Salim; David K Stammers; Brian Wynhoven; Zabrina L Brumme; Paula McKenna; Brendan Larder; S D Kemp
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity.

Authors:  David W Wright; Ilona P Deuzing; Philippe Flandre; Peter van den Eede; Micheline Govaert; Laurentia Setiawan; Peter V Coveney; Anne-Geneviève Marcelin; Vincent Calvez; Charles A B Boucher; Nancy Beerens
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.